All stock lists
Aktis Oncology, Inc. (NASDAQ:AKTS)
US · Delayed Price · Currency is USD
15.73-1.03 (-6.15%)
Insider Score
––Not scored
AKTS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
AKTS analyst forecast
AKTS analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
AKTS 12-month price target
$36.75+132.4% upsideaverage of 4 firms
$40.00High
$35.00Low
Best analysts covering AKTS
No firm covering AKTS has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
AKTS analyst ratings
| Analyst | Firm | Rating | Price target | Upside | Action | Date |
|---|---|---|---|---|---|---|
| — | Wedbush | Outperform | — | — | Reiterated | 2026-10-02 |
| Wedbush | — | $35.00 | +40.0% | — | 2026-08-19 | |
| BMO Capital | — | $37.00 | +48.0% | — | 2026-08-18 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-07-14 |
| Raymond James | — | $40.00 | +93.3% | — | 2026-06-15 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-02 |
| H.C. Wainwright | — | $35.00 | +78.5% | — | 2026-06-02 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-31 |
| — | Piper Sandler | Neutral | — | — | Downgraded | 2024-01-04 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2023-09-07 |
| — | B. Riley Securities | Neutral | — | — | Downgraded | 2023-09-07 |
| — | Roth MKM | Buy | — | — | Reiterated | 2023-05-09 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2023-05-09 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2022-11-15 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2022-09-13 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2022-05-03 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2021-11-02 |
| — | Roth Capital | Buy | — | — | Reiterated | 2021-05-04 |
| — | Roth Capital | Buy | — | — | Reiterated | 2021-01-04 |
| — | Northland Capital Markets | Market Perform | — | — | Reiterated | 2019-12-20 |
| — | Northland Capital Markets | Market Perform | — | — | Downgraded | 2019-09-18 |
| — | Northland Capital Markets | Outperform | — | — | Upgraded | 2019-07-10 |
| — | Northland Capital Markets | Market Perform | — | — | Downgraded | 2019-02-05 |
AKTS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-30 | -21.59 | -18.19 | $3.3M | $1.9M |
| 2026-05-11 | -0.31 | -0.38 | $1.9M | $3.2M |
| 2026-08-13 | -0.43 | -0.44 | $2.6M | $3.4M |
| 2026-11-12 | -0.47 | 0.00 | $4.0M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.